Thelansis

Frontotemporal Dementia (FTD) Market Outlook Thelansis’s “Frontotemporal Dementia (FTD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Frontotemporal Dementia (FTD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on t...

Frontotemporal Dementia (FTD) Market Outlook Thelansis’s “Frontotemporal Dementia (FTD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Frontotemporal Dementia (FTD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Frontotemporal Dementia (FTD) Overview Frontotemporal dementia (FTD) refers to a group of neurodegenerative disorders collectively termed frontotemporal lobar degeneration (FTLD), characterized by progressive decline in behavior, personality, language, or movement. The three main clinical syndromes are behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary p...

 Frontotemporal dementia (FTD) is a range of neurodegenerative disorders characterized by diverse clinical manifestations and two main underlying neuropathological profiles. Within FTD, there are typically three distinct clinical syndromes: behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary progressive aphasia (nfvPPA). Furthermore, FTD often exhibits clinical and neuropathological overlaps with three other neurodegenerative conditions: corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS). These syndromes can be associated with different underlying neuropathological diagnoses collectively termed frontotemporal lobar degeneration (FTLD). The most prevalent forms of FTD are as follows: 1.        Frontal variant: This type primarily impacts behavior and personality. 2.        Primary p...

  Frontotemporal dementia (FTD) describes a cluster of neurocognitive syndromes that present with impairment of executive functioning, behavioural changes, and a decrease in language proficiency. FTD is the second most common form of dementia in people under the age of 65, and its prevalence is expected to rise as the population ages. FTD is a highly heritable disorder despite varying heritability among different clinical syndromes and subtypes due to various gene mutations. Up to 50% of FTD cases with autosomal-dominant inheritance report a family history of FTD. Clinical diagnoses include behavioural variant FTD (bvFTD); primary progressive aphasia (PPA), which affects language; and disorders that primarily affect movement, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). The annual prevalence of FTDs varies between 18 to 25 cases per 100,000 population in the USA. Thelansis’s “Frontotemporal Dementia (FTD) Market Outlook, Epidemiology, C...